Trisenox(arsenic trioxide)
Arsenic Trioxide, Trisenox (arsenic trioxide) is a small molecule pharmaceutical. Arsenic trioxide was first approved as Trisenox on 2000-09-25. It is used to treat promyelocytic leukemia acute in the USA. It has been approved in Europe to treat promyelocytic leukemia acute.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Arsenic trioxide, Trisenox (discontinued: Arsenic trioxide, Trisenox)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| arsenic trioxide | ANDA | 2024-11-02 |
| trisenox | New Drug Application | 2023-09-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| promyelocytic leukemia acute | — | D015473 | C92.4 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ARSENIC TRIOXIDE, TRISENOX, CEPHALON | |||
| 2025-01-12 | ODE-167 | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9017 | Injection, arsenic trioxide, 1 mg |
Clinical
Clinical Trials
147 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia | D007951 | — | C92 | 9 | 12 | 3 | — | 2 | 22 |
| Myelodysplastic syndromes | D009190 | — | D46 | 6 | 15 | 2 | — | — | 19 |
| Preleukemia | D011289 | — | — | 6 | 15 | 2 | — | — | 19 |
| Syndrome | D013577 | — | — | 6 | 13 | 2 | — | — | 17 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 8 | 3 | — | 2 | 16 |
| Carcinoma | D002277 | — | C80.0 | 2 | 6 | 1 | — | — | 7 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | 4 | 1 | — | 1 | 6 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 5 | 1 | — | — | 5 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 4 | 1 | — | — | 4 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 2 | 1 | — | 1 | 4 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 9 | 12 | — | — | — | 17 |
| Plasma cell neoplasms | D054219 | — | — | 9 | 12 | — | — | — | 17 |
| Plasmacytoma | D010954 | — | C90.3 | 5 | 8 | — | — | — | 11 |
| Neoplasms | D009369 | — | C80 | 3 | 5 | — | — | 1 | 9 |
| Lymphoma | D008223 | — | C85.9 | 3 | 5 | — | — | 2 | 9 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 3 | 4 | — | — | — | 5 |
| Glioma | D005910 | EFO_0000520 | — | 4 | 1 | — | — | — | 4 |
| Central nervous system neoplasms | D016543 | — | — | 3 | 2 | — | — | — | 4 |
| Nervous system neoplasms | D009423 | — | — | 3 | 2 | — | — | — | 4 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 4 | — | — | — | 4 |
Show 48 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Essential thrombocythemia | D013920 | — | D47.3 | 1 | — | — | — | — | 1 |
| Polycythemia vera | D011087 | — | D45 | 1 | — | — | — | — | 1 |
| Thrombocytosis | D013922 | HP_0001894 | D75.83 | 1 | — | — | — | — | 1 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 1 | — | — | — | — | 1 |
| Gata2 deficiency | D000077428 | — | D46.22 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 2 | 2 |
| Coronary disease | D003327 | — | — | — | — | — | — | 2 | 2 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | — | 2 | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 2 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 2 | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | — | — | — | — | 1 | 1 |
| Torsades de pointes | D016171 | EFO_0005307 | I47.21 | — | — | — | — | 1 | 1 |
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Arsenic trioxide |
| INN | — |
| Description | Arsenic trioxide, sold under the brand name Trisenox among others, is an inorganic compound with the formula As2O3. As an industrial chemical, its major uses include the manufacture of wood preservatives, pesticides, and glass. It is also used as a medication to treat a type of cancer known as acute promyelocytic leukemia. For this use it is given by injection into a vein.
|
| Classification | Small molecule |
| Drug class | Antineoplastic agent |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O1[As]2O[As]3O[As]1O[As](O2)O3 |
Identifiers
| PDB | — |
| CAS-ID | 1327-53-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2362016 |
| ChEBI ID | 30621 |
| PubChem CID | 261004 |
| DrugBank | DB01169 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,565 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arsenic trioxide, Trisenox
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,218 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use